[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"epidermolysis-bullosa-dystrophica\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:epidermolysis-bullosa-dystrophica":22},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,36,63],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":20,"conditions":21,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":24,"lastUpdatePostDateStruct":25,"startDateStruct":28,"completionDateStruct":30,"leadSponsor":32,"locationsCount":35},"100134414","characteristics-of-patients-with-recessive-dystrophic-epidermolysis-bullosa-100134414",false,"NCT01019148","Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa","Inclusion Criteria:\n\n* Clinical diagnosis of RDEB by local dermatologist\n* 7 years of age or older\n\nExclusion Criteria:\n\n-Medical instability limiting ability to travel to Stanford University Medical Center","ALL",{"count":17,"type":18},70,"ESTIMATED","OBSERVATIONAL","Recessive dystrophic epidermolysis bullosa (RDEB) is a disease caused by genetic mutations in the gene for type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening subjects with RDEB to evaluate characteristics of the subjects and their cells in order to develop new strategies of therapy and determine whether subjects could be candidates for treatment studies.",[22],"Epidermolysis Bullosa Dystrophica","RECRUITING","2026-04-21",{"date":26,"type":27},"2026-04-24","ACTUAL",{"date":29,"type":27},"2009-11-10",{"date":31,"type":18},"2029-12-31",{"name":33,"class":34},"Stanford University","OTHER",1,{"id":37,"slug":38,"hasResults":11,"nctId":39,"briefTitle":40,"officialTitle":40,"acronym":4,"eligibilityCriteria":41,"healthyVolunteers":11,"sex":15,"minAge":42,"maxAge":4,"enrollmentInfo":43,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":45,"conditions":46,"keywords":49,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":35},"100559383","a-natural-history-study-of-corneal-abrasions-in-patients-with-dystrophic-epidermolysis-bullosa-deb-100559383","NCT06563414","A Natural History Study of Corneal Abrasions in Patients With Dystrophic Epidermolysis Bullosa (DEB)","Inclusion Criteria:\n\n1. The subject or their respective legal guardian must have read, understood, and signed an Institutional Review Board (IRB) approved Informed Consent\u002FAssent Form and must be able to and willing to follow study procedures and instructions.\n2. Age 6 months or older at time of Informed Consent\u002FAssent.\n3. Prior genetic diagnosis of DEB due to mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.","6 Months",{"count":44,"type":18},40,"This study is a non-interventional, observational study that will evaluate the natural history of corneal abrasions in patients with Dystrophic Epidermolysis Bullosa (DEB).",[22,47,48],"Epidermolysis Bullosa Dystrophica, Recessive","Epidermolysis Bullosa Dystrophica Dominans",[50,51,52],"Dystrophic Epidermolysis Bullosa","DEB","Corneal Abrasions","2025-07-01",{"date":55,"type":27},"2025-07-02",{"date":57,"type":27},"2024-08-02",{"date":59,"type":18},"2025-12",{"name":61,"class":62},"Krystal Biotech, Inc.","INDUSTRY",{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":15,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":19,"phases":4,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":23,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":87},"100529713","study-of-the-blood-and-skin-immunological-profile-of-patients-with-recessive-dystrophic-epidermolysis-bullosa-in-vivo-analysis-and-the-impact-of-placental-stem-cells-in-vitro-100529713","NCT06177353","Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro","Etude du Profil Immunologique Sanguin et cutané Des Patients Atteints d'épidermolyse Bulleuse Dystrophique récessive : Analyses in Vivo et Impact Des Cellules Souches Placentaires in Vitro","ISTRADEB","Inclusion Criteria:\n\nEBDR patients :\n\n* Patients aged 18 to 80 years old\n* Clinically, histologically, and\u002For genetically confirmed intermediate, reversed or generalized, moderate to severe EBDR\n\nHealthy controls :\n\n* Adults aged 18 to 80 years old\n* PBMC healthy donors: subjects who have donated blood to the EFS according to the indication criteria who have consented to the use of their samples for research purposes.\n* Healthy skin biopsy donors: subjects undergoing abdominoplasty scheduled in plastic surgery and who have given their consent for the collection of a skin biopsy from post-operative abdominoplasty skin remnants.\n* Healthy donors of bandages soiled with exudates from cutaneous wounds: subject consulting a plastic surgery department as part of their usual post-operative follow-up, who have given their consent for the collection of one of their dressings during their usual during their usual renewal.\n\nFor all subjects :\n\n* Free, informed, written consent, signed by the person and the investigator no later than the day of inclusion and before any examination carried out as part of the study.\n* Person affiliated or benefiting from a social security scheme\n\nExclusion Criteria:\n\nEBDR patients :\n\n* EBH with no definite diagnosis or other than EBDR intermediate, reversed or generalized\n* Systemic anti-inflammatory or immunosuppressive therapy for less than one month\n* Refusal of skin biopsy\n\nHealthy controls :\n\n* Acute or chronic systemic or cutaneous inflammatory disease at the time of sampling\n* Current immunosuppressive anti-inflammatory treatment in the month prior to sampling\n\nFor all subjects:\n\n* Persons under guardianship or curatorship, or deprived of their liberty by judicial or administrative decision\n* Patients receiving State Medical Aid\n* Pregnant or breast-feeding women",true,"18 Years","80 Years",{"count":75,"type":18},30,"Patients with recessive dystrophic epidermolysis bullosa (RDEB) suffer from acute and chronic post-bullous wounds along with impaired skin healing. These issues are attributed not only to mucocutaneous fragility and abnormal healing directly related to quantitative and\u002For qualitative constitutional abnormalities of collagen VII but also to a contingent cutaneous and systemic inflammatory component. This inflammatory aspect contributes to the perpetuation of skin lesions and delayed healing. Our primary objective is to define the systemic immunological\u002Finflammatory signature of patients with RDEB with an aim to develop a strategy that involves using stem cells with high immunomodulatory\u002Fanti-inflammatory capacity such as allogeneic placental stem cells (WJ-MSCs and trophoblasts).",[22],"2024-07-15",{"date":80,"type":27},"2024-07-17",{"date":82,"type":27},"2024-04-15",{"date":84,"type":18},"2025-04-15",{"name":86,"class":34},"Assistance Publique - Hôpitaux de Paris",2]